Amgen stock trades near 52-week high as Q2 2026 beat and Repatha growth support valuation

Published on 09/02/2026 at 09:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock is trading close to its recent 52-week high as of early September 2026, supported by a solid Q2 2026 earnings beat, stronger margins and double-digit growth in cholesterol drug Repatha, even as regulators scrutinize parts of its rare-disease portfolio.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin, die mit Pipette und Zellkultur-Proben im Labor arbeitet — Amgen Inc. (ISIN US0311621009) inspirierte diese dokumentarische Schwarzweiß-Aufnahme einer Forscherin im Biotech-Labor, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) stock is trading around 439.23 USD on its Nasdaq listing as of September 2, 2026, valuing the biotechnology group at about 236.86 billion USD according to Robinhood market data.

Q2 2026 earnings beat and margin trends

According to an overview of recent analyst forecasts compiled by MarketBeat, Amgen reported earnings per share of 6.29 USD for its most recent quarter ended June 30, 2026, versus a consensus expectation of 5.62 USD, meaning EPS came in 0.67 USD above analysts' projections in that period.

The same MarketBeat summary states that Amgen generated quarterly revenue of 10.05 billion USD in the June 30, 2026 quarter, compared with 9.43 billion USD expected by analysts, and that revenue increased 9.5 percent year over year, underscoring that top-line growth is now clearly outpacing many large-cap peers in the sector.

Guidance and valuation context

Looking ahead, Amgen has set its fiscal year 2026 guidance for earnings per share at a range of 22.30 to 23.50 USD, according to an analyst note summarized by MarketBeat, which suggests that even after the recent share price strength, the stock trades at a forward earnings multiple in the low 20s on this range.

Data compiled by Yahoo Finance show that Amgen's trailing twelve month revenue stood at 38.09 billion USD as of the most recent quarter ended June 30, 2026, while diluted EPS over the same period was 16.09 USD, with a profit margin of 22.95 percent, highlighting the company's ability to convert a significant share of sales into bottom-line earnings.

Go deeper

Further coverage of Amgen stock and key figures

More articles, charts and regulatory filings on Amgen stock are available in the Ad-hoc-news.de dossier for this ISIN.

More on Amgen stock at ad-hoc-news.de Investor Relations

Product focus on Repatha cholesterol therapy

A report on Amgen's cardiovascular franchise cited by Pluang notes that cholesterol-lowering drug Repatha achieved sales growth of 37 percent year over year in a recent reporting period, illustrating how this product is emerging as one of the key growth drivers within Amgen's portfolio.

Stock price context and closing level

As of September 2, 2026, data from Robinhood indicate that Amgen shares traded in an intraday range between 429.88 USD and 439.23 USD on the Nasdaq, with the last quoted price at 439.23 USD and trading volume of 2.36 million shares, slightly above an average daily volume of 2.26 million shares.